Viyash Scientific Limited Holds 41st AGM on August 11, 2026
Viyash Scientific Limited held its 41st AGM on August 11, 2026, via VC/OAVM. Key resolutions included adopting FY26 financial statements, re-appointing directors, and ratifying cost auditor remuneration. E-voting results will be announced later.
The announcement pertains to a routine Annual General Meeting, which is a standard corporate governance event. It does not involve any new financial results, strategic decisions, or major corporate actions that would significantly impact the company's stock price or operations.
The announcement details the proceedings of the Annual General Meeting, including resolutions voted upon. It is a routine corporate event and does not contain information that suggests a positive or negative shift in the company's outlook.
Viyash Scientific Limited (formerly Sequent Scientific Limited) held its 41st Annual General Meeting (AGM) on Tuesday, August 11, 2026. The meeting commenced at 4:00 PM IST and concluded at 4:55 PM IST, conducted via Video Conference (VC) / Other Audio Video Means (OAVM) in compliance with regulatory circulars.
The AGM was attended by key management personnel including Dr. Kamal Sharma (Independent Director and Chairperson), Mr. Milind Sarwate (Independent Director), Ms. Revati Kasture (Independent Director), Dr. Hari babu Bodepudi (Managing Director & Group CEO), Mr. Rajaram Narayanan (Wholetime Director & CEO - Animal Health), Mr. Srinivas Vasireddy (Wholetime Director), Mr. Anuj Poddar (Non-Executive Director), Mr. Ramakant Singani (Chief Financial Officer), and Ms. Yoshita Vora (Company Secretary). Mr Amit Jain and Mr Abhiroop Jayanthi, Non-Executive Directors, were unable to attend.
During the meeting, the Chairman, Dr. Kamal Sharma, addressed the members, followed by a detailed performance overview, key developments, and strategic focus presented by the Managing Director & Group CEO, Dr. Haribabu Bodepudi. Queries from members were addressed by Dr. Bodepudi. The resolutions put to vote included the adoption of Audited Financial Statements for the Financial Year ended March 31, 2026, re-appointment of directors Dr. Haribabu Bodepudi and Mr. Rajaram Narayanan, ratification of revised remuneration for the Cost Auditor for FY 2025-2026 and FY 2026-2027, and adoption of a new set of Articles of Association. The results of the e-voting process will be announced within statutory timelines and intimated to the stock exchanges.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.